Miozac (Dobutamine Hydrochloride)

Dobutamine Hydrochloride, the active ingredient in Miozac, is a Beta-1 adrenergic agonist presented as an injectable solution for intravenous use. It increases myocardial contractility and cardiac output in patients experiencing acute heart failure or cardiogenic shock. It is indicated for rapid hemodynamic support when conventional therapies are insufficient.

GNH USA supplies Miozac as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and intensive care units worldwide. The company adheres to stringent quality standards and provides reliable logistics for critical care medicines across global markets.

Dobutamine acts as a beta‑1 adrenergic inotrope to improve cardiac performance in acute circulatory disorders.

Acute heart failure: enhances cardiac output and reduces symptoms of low perfusion. Cardiogenic shock: restores hemodynamic stability by increasing contractility and blood pressure. Low cardiac output states: supports circulation when other inotropes are inadequate.

Dobutamine may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Tachycardia: rapid increase in heart rate that may be symptomatic. - Hypertension: elevated blood pressure, sometimes requiring monitoring. - Headache: mild to moderate head discomfort occurring during infusion. - Nausea: feeling of sickness or urge to vomit, often transient.

Serious or Rare Side Effects: - Myocardial ischemia: reduced blood flow to heart muscle that can cause chest pain. - Severe arrhythmias: life‑threatening irregular heart rhythms such as ventricular tachycardia. - Pulmonary edema: fluid accumulation in the lungs leading to breathing difficulty. - Anaphylactic reaction: severe allergic response with rash, swelling, and possible airway compromise.

When using Dobutamine, careful clinical monitoring and specific precautions are essential to ensure patient safety. - Cardiac monitoring: continuous ECG and arterial pressure monitoring should be maintained during infusion. - Dose titration: adjust infusion rate based on hemodynamic response and target parameters. - Renal impairment: monitor fluid balance and electrolytes closely in patients with kidney dysfunction. - Concomitant vasopressors: use with caution as combined effects may alter blood pressure. - Pregnancy: consider only if potential benefits justify potential risks to the fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Dobutamine can interact with several medications, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Beta‑blockers: may blunt Dobutamine’s inotropic effect, reducing therapeutic benefit. - MAO inhibitors: increase risk of hypertensive crisis when combined. - Tricyclic antidepressants: elevate risk of arrhythmias during therapy. - Non‑dihydropyridine calcium channel blockers: may potentiate negative inotropic actions.

Moderate Interactions (Monitor Closely): - Diuretics: electrolyte shifts can modify cardiac response to Dobutamine. - ACE inhibitors: additive hypotensive effect may require blood pressure monitoring.